Lurbinectedin: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Lurbinectedin appears in the FDA drug-label database. Marketed as ZEPZELCA.
- Drug class
- Alkylating Drug (FDA established pharmacologic class)
- Mechanism of action
- Alkylating Activity (as stated on the FDA label)
FDA-approved use
ZEPZELCA is an alkylating drug indicated: • in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. ( 1.1 ) • For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.2 ) 1.1 Extensive-Stage Small Cell Lung Cancer ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. 1.2 Metastatic Smal…
Phase breakdown
Conditions being studied
Recruiting trials involving Lurbinectedin
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
- Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
- Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
- Study of Trilaciclib and Lurbinectidin
Common questions
Is Lurbinectedin FDA-approved?
Yes, marketed as ZEPZELCA.
How many recruiting trials involve Lurbinectedin?
12 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.